Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs JetBlue Airways Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while JetBlue Airways Corporation trades at $5.33 (market cap $1.99B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| BIO | JBLU | |
|---|---|---|
Market Cap | $8.04B | $1.99B |
Sector | Health | Industrials |
52-Week High | $339.75 | $6.46 |
52-Week Low | $241.71 | $4.03 |
Enterprise Value | $7.85B | $9.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
JetBlue (JBLU) trades at $5.60, down 2.78% on the day, with a neutral technical signal and mixed fundamental picture. The airline reported negative net income margins of -7.78% and has missed earnings expectations in recent quarters, though it beat in Q3 2025. Recent news highlights expansion at Fort Lauderdale airport and sector-wide pressure from fuel costs. Analyst consensus is mixed with 61% hold ratings and a $5.12 price target slightly below current levels.
The outlook remains challenging with persistent losses and high debt levels, though strategic expansions and potential fuel cost relief offer some upside. Key risks include competitive pressures, volatile fuel prices, and execution of turnaround efforts. The stock presents a speculative opportunity for investors betting on operational improvements amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
